Ventripoint Diagnostics has received an acceptance review notification concerning its recent 510(k) submission to US Food and Drug Administration (FDA) to expand the use of Ventripoint Medical System (VMS) heart analysis system to all types of heart disease.

The notification confirms the submission contains all necessary elements and information needed to proceed with the substantive review, for which a lead reviewer has been assigned.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The FDA guidelines mandate that the company receive its first communication regarding the submission within 60 days, with closure of the submission expected to occur within 90 days.

"The company developed tools to monitor patients with heart disease and VMS is the first cost-effective and accurate tool for measuring right ventricle heart function."

The submission includes the addition of the company’s newest catalogue, Right Ventricle, which was developed to provide right ventricular volumes of individuals being evaluated, regardless of their cardiac diagnosis.

According to the company, clearance by the FDA will greatly increase the utility and market adoption of the VMS.

See Also:

Ventripoint CEO Dr George Adams said: "We are extremely pleased with how quickly this process has been going so far, which is a true testament to our development and regulatory team. We look forward to the US-FDA’s response in the next 60 days."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company developed tools to monitor patients with heart disease and VMS is the first cost-effective and accurate tool for measuring right ventricle heart function.

It has a suite of applications for all major heart diseases and imaging modalities such as congenital heart disease, left or right heart failure and normal hearts.